Dupixent shows consistent, long-term efficacy in real-world studies
Click Here to Manage Email Alerts
MIAMI BEACH, Florida — In two-real world studies, Dupixent treatment led to similar rapid and sustained improvements in patients with atopic dermatitis, according to a poster presentation at South Beach Symposium.
Dupixent (dupilumab), a fully monoclonal antibody that blocks the shared receptor component for interleukin (IL)-4 and IL-13, is approved for the treatment of patients with moderate to severe AD not adequately controlled by prescription medications.
“Clinical trials have exclusion criteria that may result in a different, maybe healthier, cohort than the group of patients treated in the real world,” Jerry Bagel, MD, of the Psoriasis Treatment Center of Central New Jersey, told Healio.
In this analysis, researchers compared two real world studies, RELIEVE-AD and PROSE, which both evaluated the efficacy and health-related quality of life (HRQoL) outcomes of patients with AD treated with dupilumab.
RELIEVE-AD, a prospective, observational, real-world study, that used an online database to assess the efficacy of dupilumab in 698 patients (mean age, 46.2 years; 38.3% men; 73.7% white) with AD aged 18 years and older.
PROSE, an ongoing, prospective, observational, multicenter registry study, included 764 patients (mean age, 40.5 years; 41.5% male; 55% white) with AD aged 12 years and older from in the United States and Canada.
Both studies utilized a Numeric Rating Scale (NRS), with higher scores indicating a worse outcome, to assess the effect of dupilumab on skin symptoms including pain or sores, a feeling of hot burning skin and sensitivity. The researchers used DLQI to assess HRQoL.
Results showed extremely similar findings in both studies. RELIEVE-AD patients started with baseline NRS scores of 5.9 in skin pain, 5.2 in hot or burning skin and 5.5 in skin sensitivity. After 30 to 36 months of follow up, scores had reduced to 1.5, 1.2 and 1.2, respectively.
PROSE displayed the same findings with baseline NRS scores of 5.4, 4.7 and 5.2 in the respective categories, which decreased to 1.3, 1.1 and 1.4 after 24 months.
HRQoL improvements were also similar between studies. RELIEVE-AD patients’ mean DLQI score decreased from 14.4 at baseline to 3.2 after 30 to 36 months, whereas PROSE patients’ mean score decreased from 13.3 to 3.7 after 24 months.
“Dupixent’s efficacy in the real-world setting substantiates its efficacy,” Bagel told Healio.
Collapse
Bagel J, et al. Real-world effectiveness of dupilumab in atopic dermatitis: Consistency in rate and magnitude of improvement across observational study methodologies. Presented at: South Beach Symposium; Feb. 9-12, 2023; Miami Beach, Fla.
Click Here to Manage Email Alerts